doi: 10.1016/j.clinre.2016.11.009 Summary Keywords glucagon-like peptide-1 receptor agonists, metabolic disease, metabolic dysfunction-associated steatotic liver disease, public health, umbrella review Citation Wu H, Zhang Z-H, Ye T, Chen J-N, Tung T-H and Zhu J-S (2026) Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review
Clinical trials have demonstrated reductions in hemoglobin A1c levels and weight loss that vary by dose and populationwith higher doses (such as Wegovy 2.4 mg) achieving approximately 15% weight loss in obesity trials, with more modest effects at lower doses used for diabetes
If patients discontinue GKP-1 agonists and regain the weight they lost, what implications does this have for their psoriasis
Every threshold and reward was thoughtfully selected to maximize AOV: 1 Spend TWD 1,200 : Get a perfume pendant